Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.

Wajja A., Nassanga B., Natukunda A., Serubanja J., Tumusiime J., Akurut H., Oduru G., Nassuuna J., Kabagenyi J., Morrison H., Scott H., Powell Doherty R., Marshall JL., Cabrera Puig I., Cose S., Kaleebu P., Webb EL., Satti I., McShane H., Elliott AM., TB042 Study Team None.

DOI

10.1016/S1473-3099(23)00758-2

Type

Journal

Lancet Infect Dis

Publication Date

02/2024

Volume

24

Pages

e78 - e79

Keywords

Humans, BCG Vaccine, Tuberculosis Vaccines, Tuberculosis, Vaccines, DNA, Mycobacterium tuberculosis, Antigens, Bacterial

Permalink Original publication